Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 45Breast Neoplasms 39Triple Negative Breast Neoplasms 19Prostatic Neoplasms 17Neoplasms 13Fallopian Tube Neoplasms 13Endometrial Neoplasms 12Recurrence 8Pancreatic Neoplasms 8Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Lung Neoplasms 6Carcinoma, Ovarian Epithelial 6Glioma 5Glioblastoma 5Carcinoma, Renal Cell 5Uterine Cervical Neoplasms 4Sarcoma 4Carcinoma, Squamous Cell 4Carcinoma, Non-Small-Cell Lung 4Advanced Breast Cancer 4Stomach Neoplasms 3Solid Tumor 3Melanoma 3Head and Neck Neoplasms 3Fanconi Anemia, Complementation Group D1 3Uveal Melanoma 2Uterine Neoplasms 2Urinary Bladder Neoplasms 2

Interventions

pembrolizumab 1olaparib 1Oxaliplatin 1Nivolumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Urothelial Cancer × olaparib × Clear all
NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Hoosier Cancer Research Network

Phase 2 Completed
19 enrolled 9 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡